Recent briefings noted that mid-July 2026 macro conditions were shaped by escalating military tensions around the Strait of Hormuz, which drove Asian LNG spot prices up 10% to $20.2/MMBtu — the highest level since March — contributing to broader equity market pressure during the European session [Brief - 2026-07-16]. An ABT-specific update was published in August covering Q2 2026 filings and holdings activity [Brief - 2026-08-15].
Abbott Laboratories reported trailing twelve-month revenue of $45.13 billion as of 31 March 2026, reflecting year-over-year growth of 7.78%. Net income over the same period stood at $6.28 billion, with a net margin of 13.91% and an operating margin of 17.07%. Gross margin was recorded at 37.08%. EPS declined 19.74% year-over-year. The company held $6.80 billion in cash against total debt of $29.64 billion. The P/E ratio was 28.95 [SEC 10-Q - ABT - 2026-03-31].
Insider activity in September 2026 comprised eight transactions with a net direction of selling, totalling a net disposal value of approximately $46.21 million [SEC Form 4 - ABT - 2026-09]. On the institutional side, five notable investors opened new positions in ABT during the most recent reporting period: Citadel (Ken Griffin), Millennium (Izzy Englander), AQR Capital (Cliff Asness), Bridgewater (Ray Dalio), and Soros Fund Management (George Soros) each initiated positions [SEC 13F - Citadel - Q2 2026; SEC 13F - Millennium - Q2 2026; SEC 13F - AQR Capital - Q2 2026; SEC 13F - Bridgewater - Q2 2026; SEC 13F - Soros Fund Mgmt - Q2 2026].
The prevailing macro backdrop as of the report generation date shows the 10-year US Treasury yield at 4.83% and the 2-year yield at 4.39%, producing a normal yield curve with a spread of 44 basis points [FRED DGS10; FRED DGS2]. This report was generated in response to recent material insider selling activity and the concurrent opening of new institutional positions across multiple prominent fund managers.